Test drug to block DNA damage in triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have invasive triple-negative breast cancer (ER-, PR-, and HER2-negative).
- You’re planning curative breast surgery after at least 6 cycles of neoadjuvant chemotherapy.
- After chemotherapy, scans must show a measurable remaining tumor that can be targeted for marker placement and repeat biopsies.
- Your health and strength for treatment are good enough (ECOG 0–1) and you can complete at least 2 weeks of pre-surgery trial treatment.
- You must be willing to have a baseline biopsy right before/at the start window and another biopsy on Day 14; if biopsies are unsafe, you can’t join.
- You must not have cancer spread to distant organs (metastatic disease), and you must have no recent second cancer (with limited exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
This trial tests a chemotherapy drug (temozolomide) alone or combined with a targeted therapy (olaparib) for people with triple negative breast cancer. It may help if your tumor has a specific genetic marker (MGMT promoter methylation).
Hear when a new Breast Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.